
"Mesothelioma remains a challenging disease with generally poor prognosis, and there is a large unmet medical need for new, innovative treatments such as ONCOS-102..."

"Mesothelioma remains a challenging disease with generally poor prognosis, and there is a large unmet medical need for new, innovative treatments such as ONCOS-102..."

"Having obtained an encouraging proof-of-concept for the liver-cancer directed effect of MIV-818 in phase Ia, we hope to get additional supportive data from the phase Ib study. We believe that MIV-818 has the potential to provide liver cancer patients with major therapeutic benefits."

The FDA extended the Prescription Drug User Fee Act target action date for liso-cel due to the submission of additional information by the drug developer, which will require additional time to review.

“While these findings cannot be exploited to improve clinical decision making today, our results, and the underlying data, collected on an increasingly rare group of triple-negative breast cancer patients treated with locoregional therapy alone, are a valuable contribution to ongoing research on the development, progression and ultimate treatment of triple-negative breast cancer."

"It’s extremely gratifying to see positive results for this important trial exploring the combination of umbralisib and ublituximab in patients with both front-line and relapsed/refractory CLL."

The study results indicated clinical efficacy against central nervous system metastases in a cohort of patients. Almonertinib also displayed an overall favorable safety profile.

Results from the phase Ib/II study of VERU-111 in patients with metastatic castration-resistant prostate cancer have prompted plans to meet with the FDA in the third quarter of 2020 to discuss the trial design for a phase III clinical trial of VERU-111 for this indication.

"...These important new results further demonstrate Libtayo’s potential in patients with difficult-to-treat, non-melanoma skin cancers."

“We are excited to partner with AON to continue to bring the same level of patient care and compassion coupled with access to additional services that will benefit our patients."

A safety, tolerability, pharmacokinetics, and preliminary efficacy of avadomide in patients with advanced solid tumors, non-Hodgkin lymphomas, or multiple myeloma shows evidence of preliminary activity. Findings from the diffuse large B-cell cohort were published in Blood.

A new phase II trial showed higher pathological complete response rates in patients with HER2-positive breast cancer who took docetaxel, carboplatin, trastuzumab, and pertuzumab followed by trastuzumab emtansine, and pertuzumab, versus those who took only the former therapy.

“This combined genomic and epigenomic plasma-based ctDNA test continues to demonstrate high sensitivity and specificity which significant implications for its clinical utility of CRC detection,”

There is a significant unmet clinical need [for] treatment of CML globally. This Orphan Drug Designation from FDA marks a major milestone for HQP1351..."

In an interview with Targeted Oncology, Bruce L. Levine, PhD, discussed hot topics in the treatment landscape of melanoma, including the development of chimeric antigen receptor T and NK cells.

“Immune transcriptomic analyses of in silico and wet-lab cohorts of TP53-mutated AML suggest the presence of high T-cell infiltration and high expression of immune checkpoints and interferon-gamma signaling molecules compared with AML subgroups with other risk-defining molecular lesions."

In an interview with Targeted Oncology, Michael A. Davies, MD, PhD, discussed the current treatment landscape of melanoma and the recent advances that have provided a great level of optimism to what has been known to be a very challenging cancer setting.

"Atezolizumab combined with vemurafenib and cobimetinib showed a statistically significant and clinically meaningful in progression-free survival via investigator assessment when compared with placebo plus vemurafenib and cobimetinib."

In an interview with Targeted Oncology, Gregory L. Beatty, MD, PhD, discussed the science behind the development of metastases in pancreatic tumors, including how metastases differ in various sites in the body. He also reviewed the treatment options for this disease.

In an interview with Targeted Oncology, Sarat Chandarlapaty, MD, PhD, explained the mechanisms of resistance to CDK4/6 inhibitors. He also discussed new therapeutic strategies are being curated and implemented to overcome resistance in patients with ER-positive breast cancer.

Targeted Oncology reviews trending news online for the week of May 1, 2020, including recent updates from studies of COVID-19 and the latest oncology news.

The FDA has approved the use of daratumumab in combination with hyaluronidase-fihj (Darzalex Faspro) for the treatment of adult patients with newly diagnosed or relapsed/refractory multiple myeloma. The newly approved product allowed for subcutaneous dosing of daratumumab.

“The results that we’ve seen do suggest that there is some interaction between the two drugs, despite ongoing debate of whether this regimen after progression on a PD-1 inhibitor could be beneficial in clear cell renal cell carcinoma."

"The acceptance of our submission for CC-486 represents an important step towards a potential new maintenance treatment to address an urgent medical need for patients with AML and we look forward to working with the FDA during its review of CC-486."

The electrical impedance spectroscopy system , Nevisense 3.0, a third-generation of the SciBase Nevisense system, for the early detection of melanoma has been granted FDA approval.

Here’s a look back on the FDA happenings from the month of April 2020.

“We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing."

"As anticipated, the data continues to become more compelling with extended SGX301 treatment."

“The ATLANTIS trial reflects an exciting innovation in front-line precision cancer medicine for patients with advanced [urothelial cancer]."

"Over the last 12 years, an average of 9 practices per month have closed, been acquired by a hospital, or merged. These are troubling trends and dangerous for patients battling cancer...”

In an interview with Targeted Oncology, Elizabeth M. Swisher, MD, discussed data for PARP inhibitor maintenance therapy in patients with ovarian cancer, including the VELIA study of veliparib and the ARIEL3 trial of rucaparib.